Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 2

Conditions

Pulmonary Disease, Chronic Obstructive

Treatments

Drug: GSK159797

Study type

Interventional

Funder types

Industry

Identifiers

NCT00354666

B2E101312

Details and patient eligibility

About

This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale. This will allow comparison with previous studies which have only used inhalation of the drug as a vapour.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects with mild to moderate stable asthma but no other lung problems.
Male subjects or females who are not able to get pregnant (e.g. post-menopausal or surgically sterile).
Non-smokers.
Subjects that show a measurable improvement in the function of their lungs after a single dose of salbutamol.

Exclusion criteria

Any significant illness.
Subjects with heart problems.
Subjects who have had a cold or chest infection 2-4 weeks prior to the study.
Subjects who take medication for their asthma, or other conditions, not compatible with the study.